Century Therapeutics price target lowered to $5 from $9 at H.C. Wainwright
The Fly

Century Therapeutics price target lowered to $5 from $9 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Century Therapeutics (IPSC) to $5 from $9 and keeps a Buy rating on the shares after the company announced updated Phase 1 data for CNTY-101 in CD19+ B cell lymphomas.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App